{
    "nctId": "NCT00238290",
    "briefTitle": "Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer",
    "officialTitle": "Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 13,
    "primaryOutcomeMeasure": "Objective response rate as assessed by CT scan or MRI every 3 months",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer\n\n  * Advanced disease\n* Measurable disease, defined as \u2265 1 unidimensionally measurable lesion outside previously irradiated areas that is \u2265 20 mm OR \u2265 10 mm if the slice thickness of the CT scan or MRI is \u2264 5 mm\n\n  * No nonmeasurable lesions as the only site of measurable disease, including any of the following:\n\n    * Osteoblastic bone metastases\n    * Ascites\n    * Pleural or pericardial effusions\n    * Carcinomatous lymphangitis of the lung\n* Progressive disease after prior treatment with a nonsteroidal aromatase inhibitor (e.g., letrozole or anastrozole) in an adjuvant or advanced disease setting\n* HER-2 amplification \u2265 2 by fluorescence in situ hybridization\n* No clinical symptoms or history of CNS or leptomeningeal metastases (no imaging is required)\n* No visceral involvement with risk for organ dysfunction\n* Hormone receptor status:\n\n  * Estrogen receptor- and/or progesterone receptor-positive tumor\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal, defined by 1 of the following:\n\n  * At least 55 years of age\n  * Less than 55 years of age with spontaneous cessation of menses for \u2265 1 year\n  * Less than 55 years of age with spontaneous cessation of menses within the past year, but amenorrheic with biochemical evidence of postmenopausal status\n  * Underwent prior bilateral oophorectomy\n  * Radiation or chemically induced menopause (treatment with luteinizing hormone-releasing hormone antagonists must continue during study treatment)\n\nPerformance status\n\n* WHO 0-1\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC \u2265 3,000/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* AST and ALT \u2264 2 times upper limit of normal\n\nRenal\n\n* Creatinine clearance \\> 30 mL/min\n\nCardiovascular\n\n* No uncontrolled cardiac disease, including any of the following:\n\n  * Unstable angina\n  * Arrhythmia\n  * Hypertension\n* No history of congestive heart failure\n* No myocardial infarction within the past 6 months\n* LVEF \\> 50% by echocardiogram\n\nPulmonary\n\n* No severe dyspnea at rest\n\nOther\n\n* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer\n* No psychiatric disability that would preclude study participation or giving informed consent\n* No active autoimmune disease\n* No uncontrolled diabetes\n* No other serious underlying medical condition that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* No prior trastuzumab (Herceptin\u00ae)\n\nChemotherapy\n\n* Prior neoadjuvant or adjuvant chemotherapy allowed\n* No prior palliative chemotherapy\n\nEndocrine therapy\n\n* See Disease Characteristics\n\nRadiotherapy\n\n* See Disease Characteristics\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 1 month since prior experimental drugs on another clinical trial\n* No concurrent drugs that contraindicate study treatment\n* No other concurrent anticancer drugs\n* No other concurrent investigational drugs",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}